Common questions about Admira (FAQ)
Q: Is Admira the same type of medicine as [similar drug name]?
A: Admira contains the active ingredient Gliclazide, which belongs to a specific class of oral antidiabetic agents called sulfonylureas. While there are many medications used to manage high blood sugar, regulatory documents note that Admira differs from some other diabetes medicines in its specific molecular structure and how it stimulates the body to release insulin.
Q: What happens if I accidentally take more Admira than intended?
A: Taking more of this medicine than prescribed can cause severe hypoglycaemia (very low blood sugar). Symptoms of low blood sugar may include confusion, excessive sweating, and a rapid heartbeat. Official guidance describes the need for immediate medical attention if this accidental overdose occurs.
Q: Does Admira affect birth control pills?
A: Official information indicates that female hormones, such as those found in oral contraceptive pills, may increase blood glucose levels. Because of this, the birth control pill might reduce the blood sugar-lowering effect of Admira, and close monitoring of blood sugar levels may be necessary.
Q: Will Admira interfere with my ability to drive or operate machinery?
A: Patients are officially advised to be mindful of the symptoms of hypoglycaemia (low blood sugar), which can include dizziness or confusion. Because these symptoms may interfere with the ability to drive or operate machinery, official warnings advise caution, particularly when treatment is first started.
Q: Is the tiredness I feel from my condition or from Admira?
A: Official documents classify the most frequent adverse effect of Admira as hypoglycaemia, or low blood sugar. Symptoms of low blood sugar often include drowsiness and confusion. This is one of the documented ways the medication's primary action may be associated with such feelings.
Q: Is it normal to feel [mild, non-serious symptom] when starting Admira?
A: When starting Admira, it is important to be aware of the first signs of the most common adverse effect, which is hypoglycaemia. These initial signs are described as feeling shaky, anxious, dizzy, or sweating excessively, and patients should be made aware of these signs early in treatment, according to regulatory notes.
Q: Does Admira cause weight gain?
A: Clinical studies conducted on the modified-release formulation of Gliclazide, the active ingredient in Admira, have noted that body weight typically remains stable during the course of treatment. This observation distinguishes it from some other older diabetes medications.
Q: Are there any long-term effects of taking Admira?
A: Official research evidence has explored the use of Admira in long-term controlled clinical trials over extended observation periods. These studies examined specific patterns related to microvascular complications, such as those affecting the kidneys, and reported on non-specific adverse events over time.
Q: What is the shelf life of Admira?
A: The official shelf life is determined by the regulatory stability data for the product and is typically stated as 3 years from the date of manufacture. This information can be found printed alongside the expiration date on the product packaging.
Q: What if Admira doesn't seem to be working for me after a few months?
A: The official administration protocol includes a specific process for dose adjustment (titration) if blood sugar levels are not adequately managed. This process allows for increases in the dose up to the established maximum daily limit, which typically involves reassessment after a minimum of one month.
Q: How long does it typically take for Admira to start working?
A: The medication is expected to begin lowering blood sugar levels soon after therapy is initiated. The official protocol notes that a dose increase may be considered if blood glucose levels are not sufficiently reduced after two weeks of initial use, indicating that initial effectiveness should be evaluated around this time.
Q: How long does the effect of one dose of Admira last?
A: Admira is formulated as a modified-release tablet, which is designed to release the drug progressively over a 24-hour period. This design allows for its recommended once-daily dosing. The elimination half-life (T1/2) of the active ingredient is approximately 16 hours.
Q: Will Admira cure my condition, or just manage symptoms?
A: Official labeling and regulatory documents describe Admira as being used for the management or control of high blood sugar associated with Type 2 Diabetes Mellitus. It is not designated or described in official sources as a cure for the condition.
Q: What tests might doctors run before prescribing Admira?
A: Due to regulatory constraints, the medicine is contra-indicated (cannot be used) in patients with severe renal or hepatic impairment. Because of this, a common part of the initial evaluation involves assessing a patient’s kidney and liver function before starting therapy.
Q: What evidence supports the use of Admira for long-term treatment?
A: The support for long-term use comes from studies that have investigated effectiveness by monitoring key biomarkers like Glycated Hemoglobin ( HbA1c), which reflects average blood sugar over several months. Official research also includes observations related to long-term microvascular complications.
Q: How quickly does Admira get eliminated from the body?
A: The body breaks down the drug into by-products (metabolites and conjugates), which are eliminated primarily via the kidneys (60–70% of elimination) and to a lesser extent via the feces (10–20%).
